AR051145A1 - Composiciones analgesicas / antipireticas para absorcion potenciada - Google Patents

Composiciones analgesicas / antipireticas para absorcion potenciada

Info

Publication number
AR051145A1
AR051145A1 ARP050104491A ARP050104491A AR051145A1 AR 051145 A1 AR051145 A1 AR 051145A1 AR P050104491 A ARP050104491 A AR P050104491A AR P050104491 A ARP050104491 A AR P050104491A AR 051145 A1 AR051145 A1 AR 051145A1
Authority
AR
Argentina
Prior art keywords
analgesic
composition
antipiretic
potentiated
absorption
Prior art date
Application number
ARP050104491A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR051145A1 publication Critical patent/AR051145A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revela un método para acelerar el advenimiento de la actividad de una primera composicion analgésica/antipirética que contiene una cantidad efectiva como analgésico/antipirético de acetaminofeno, cafeína y, optativamente, aspirina, método que comprende la incorporacion, en la primera composicion, una cantidad adecuada para acelerar el advenimiento de la actividad analgésica/antipirética de por lo menos un agente alcalino, por lo cual se produce una segunda composicion, donde la segunda composicion que contiene el agente alcalino es bioequivalente a la primera composicion, pero tiene un advenimiento más rápido de la actividad analgésica/antipirética que la primera composicion.
ARP050104491A 2004-10-28 2005-10-26 Composiciones analgesicas / antipireticas para absorcion potenciada AR051145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62281204P 2004-10-28 2004-10-28

Publications (1)

Publication Number Publication Date
AR051145A1 true AR051145A1 (es) 2006-12-20

Family

ID=35744599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104491A AR051145A1 (es) 2004-10-28 2005-10-26 Composiciones analgesicas / antipireticas para absorcion potenciada

Country Status (17)

Country Link
US (1) US20070298096A1 (es)
EP (1) EP1807068B1 (es)
JP (1) JP2008518914A (es)
CN (1) CN101048155A (es)
AR (1) AR051145A1 (es)
AT (1) ATE460930T1 (es)
AU (1) AU2005302618B2 (es)
BR (1) BRPI0520000A2 (es)
CA (1) CA2583517C (es)
DE (1) DE602005020048D1 (es)
MX (1) MX2007005121A (es)
NO (1) NO20072255L (es)
PE (1) PE20061125A1 (es)
PL (1) PL1807068T3 (es)
PT (1) PT1807068E (es)
RU (1) RU2398571C2 (es)
WO (1) WO2006049978A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607085D0 (en) 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
CN100417385C (zh) * 2006-09-26 2008-09-10 林星 一种用于治疗外伤的外用制剂
GB0707489D0 (en) * 2007-04-18 2007-05-23 Renaissance Pharma Compounds
CN101596163B (zh) * 2008-06-06 2012-06-27 康美保宁（四川）制药有限公司 阿咖酚微丸制剂及其制备方法
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
CN102861040B (zh) * 2012-08-02 2014-04-23 广东环球制药有限公司 含有阿司匹林、对乙酰氨基酚和咖啡因的药物组合物及其制备方法
CN102949401A (zh) * 2012-09-06 2013-03-06 广东九明制药有限公司 对乙酰氨基酚、乙酰水杨酸和咖啡因组合物及其制备工艺
US10124005B1 (en) * 2017-12-15 2018-11-13 Lisa Josette Myslinski Multisymptom migraine combination medication
CN110711197B (zh) * 2018-07-12 2023-11-24 北京恒润泰生医药科技有限公司 阿司匹林和对乙酰氨基酚的分子复合物加咖啡因,其制备,活性及应用
CN108853124A (zh) * 2018-08-15 2018-11-23 康美保宁（四川）制药有限公司 一种阿咖酚制剂及其制剂方法
GB202007670D0 (en) * 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
CA1182049A (en) * 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
JP3122748B2 (ja) * 1991-11-29 2001-01-09 ライオン株式会社 イブプロフェン含有解熱鎮痛剤
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
JPH06227995A (ja) * 1993-02-03 1994-08-16 Takeda Chem Ind Ltd 安定化された固型製剤
JPH07206689A (ja) * 1994-01-21 1995-08-08 Barnett Lab Ltd 治療組成物および宿酔の治療のためのこの組成物の使用法
DE19502789A1 (de) * 1995-01-28 1996-08-01 Dirk Krischenowski Arzneimittel
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
JP2002012557A (ja) * 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
EP1391201A4 (en) * 2001-05-25 2004-06-30 Ssp Co Ltd MEDICAL COMPOSITIONS
JP4553552B2 (ja) * 2003-01-08 2010-09-29 日東薬品工業株式会社 生体リズム応用キット

Also Published As

Publication number Publication date
AU2005302618A1 (en) 2006-05-11
EP1807068B1 (en) 2010-03-17
CA2583517C (en) 2013-06-04
PL1807068T3 (pl) 2010-08-31
AU2005302618B2 (en) 2009-10-22
JP2008518914A (ja) 2008-06-05
CN101048155A (zh) 2007-10-03
BRPI0520000A2 (pt) 2009-04-07
DE602005020048D1 (de) 2010-04-29
NO20072255L (no) 2007-07-18
ATE460930T1 (de) 2010-04-15
MX2007005121A (es) 2007-06-22
PE20061125A1 (es) 2006-11-08
EP1807068A1 (en) 2007-07-18
CA2583517A1 (en) 2006-05-11
RU2007119641A (ru) 2008-12-10
PT1807068E (pt) 2010-04-19
WO2006049978A1 (en) 2006-05-11
RU2398571C2 (ru) 2010-09-10
US20070298096A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AR051145A1 (es) Composiciones analgesicas / antipireticas para absorcion potenciada
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
MX2007000564A (es) Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.
AR109263A2 (es) Composición que comprende moxidectina
AR061772A1 (es) Composicion de alto contenido de ion fluoruro para el cuidado oral y metodo para mantener la actividad anticaries
BRPI0514474A (pt) multiparticulados
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
ES2422217T3 (es) Concentrado de espuma para apagar incendios
DOP2006000241A (es) Composiciones farmacéuticas sólidas que contienen pregabalina
ATE486636T1 (de) Zweikomponenten-zahnbleichzusammensetzungen
AR041911A1 (es) Proceso para la preparacion de nanocompuestos de poliolefina
AR040302A1 (es) Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
AR053541A1 (es) Combinacion de xolair con agente inmunosupresor
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
ECSP11010762A (es) Composición tópica para el tratamiento de queratosis actínica
AR048895A1 (es) Composiciones para el blanqueo acelerado de dientes
CL2012001019A1 (es) Composicion farmaceutica que comprende una proenzima de proteasa seleccionada de al menos tripsinogeno y quimiotripsinogeno y un agente activo seleccionado de al menos un compuesto de selenio, un compuesto vanilloide, un agente reductor de glicolisis citoplasmica y opcionalmente una glucosidohidrolasa; y uso para tratar cancer.
BR0317924A (pt) Formas de dosagem não aquosas de composto de prostaglandina e
ECSP067050A (es) Forma de dosificacion solida de heparina humeda
BRPI0417672A (pt) processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
AR060264A1 (es) Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion
AR042652A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
AR038560A1 (es) Una composicion antitranspirante/ desodorante
AR065068A1 (es) Composicion farmaceutica que comprende tramadol y ketoprofeno en asociacion
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal